FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1098-1104 October 11, 2001 Number 15 Next

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor –Neutralizing Agent

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Infliximab is a humanized antibody against tumor necrosis factor (TNF-) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF- in association with tuberculosis may cause weight loss and night sweats, yet in animal models it has a protective role in the host response to tuberculosis. There is no direct evidence of a protective role of TNF- in patients with tuberculosis.

Methods We analyzed all reports of tuberculosis after infliximab therapy that had been received as of May 29, 2001, through the MedWatch spontaneous reporting system of the Food and Drug Administration.

Results There were 70 reported cases of tuberculosis after treatment with infliximab for a median of 12 weeks. In 48 patients, tuberculosis developed after three or fewer infusions. Forty of the patients had extrapulmonary disease (17 had disseminated disease, 11 lymph-node disease, 4 peritoneal disease, 2 pleural disease, and 1 each meningeal, enteric, paravertebral, bone, genital, and bladder disease). The diagnosis was confirmed by a biopsy in 33 patients. Of the 70 reports, 64 were from countries with a low incidence of tuberculosis. The reported frequency of tuberculosis in association with infliximab therapy was much higher than the reported frequency of other opportunistic infections associated with this drug. In addition, the rate of reported cases of tuberculosis among patients treated with infliximab was higher than the available background rates.

Conclusions Active tuberculosis may develop soon after the initiation of treatment with infliximab. Before prescribing the drug, physicians should screen patients for latent tuberculosis infection or disease.

Source Information

From the Pulmonary Center, Department of Medicine (J. Keane, E.M.-L.), and the Pathology Department (J. Kasznica), Boston University School of Medicine, Boston; and the Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, Division of Epidemiology (S.G., R.P.W., M.M.B.), and Office of Therapeutics Research and Review (W.D.S., J.N.S.), Food and Drug Administration, Rockville, Md.

Address reprint requests to Dr. Keane at the Boston University School of Medicine, Pulmonary Ctr., 80 E. Concord St., R-304, Boston, MA 02118, or at jkeane{at}lung.bumc.bu.edu.

Full Text of this Article

This article has been cited by other articles:

• MALAVIYA, A. N., KAPOOR, S., GARG, S., RAWAT, R., SHANKAR, S., NAGPAL, S., KHANNA, D., FURST, D. E. (2009). Preventing Tuberculosis Flare in Patients with Inflammatory Rheumatic Diseases Receiving Tumor Necrosis Factor-{alpha} Inhibitors in India -- An Audit Report. The Journal of Rheumatology 36: 1414-1420 [Abstract] [Full Text]  
• Rahman, S., Gudetta, B., Fink, J., Granath, A., Ashenafi, S., Aseffa, A., Derbew, M., Svensson, M., Andersson, J., Brighenti, S. G. (2009). Compartmentalization of Immune Responses in Human Tuberculosis: Few CD8+ Effector T Cells but Elevated Levels of FoxP3+ Regulatory T Cells in the Granulomatous Lesions. Am. J. Pathol. 174: 2211-2224 [Abstract] [Full Text]  
• Wilkinson, R. J., Lange, C. (2009). Vitamin D and Tuberculosis: New Light on a Potent Biologic Therapy?. Am. J. Respir. Crit. Care Med. 179: 740-742 [Full Text]  
• AGGARWAL, R., MANADAN, A. M., POLIYEDATH, A., SEQUEIRA, W., BLOCK, J. A. (2009). Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections. The Journal of Rheumatology 36: 914-917 [Abstract] [Full Text]  
• Namba, T., Tanaka, K.-I., Ito, Y., Ishihara, T., Hoshino, T., Gotoh, T., Endo, M., Sato, K., Mizushima, T. (2009). Positive Role of CCAAT/Enhancer-Binding Protein Homologous Protein, a Transcription Factor Involved in the Endoplasmic Reticulum Stress Response in the Development of Colitis. Am. J. Pathol. 174: 1786-1798 [Abstract] [Full Text]  
• Weinblatt, M. E., Abbott, G. F., Koreishi, A. F. (2009). Case 13-2009 -- A 54-Year-Old Woman with Respiratory Failure and a Cavitary Lesion in the Lung. NEJM 360: 1770-1779 [Full Text]  
• Fidder, H, Schnitzler, F, Ferrante, M, Noman, M, Katsanos, K, Segaert, S, Henckaerts, L, Van Assche, G, Vermeire, S, Rutgeerts, P (2009). Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58: 501-508 [Abstract] [Full Text]  
• Ray, J. C. J., Flynn, J. L., Kirschner, D. E. (2009). Synergy between Individual TNF-Dependent Functions Determines Granuloma Performance for Controlling Mycobacterium tuberculosis Infection. J. Immunol. 182: 3706-3717 [Abstract] [Full Text]  
• BEHAR, S. M., SHIN, D. S., MAIER, A., COBLYN, J., HELFGOTT, S., WEINBLATT, M. E. (2009). Use of the T-SPOT.TB Assay to Detect Latent Tuberculosis Infection Among Rheumatic Disease Patients on Immunosuppressive Therapy. The Journal of Rheumatology 36: 546-551 [Abstract] [Full Text]  
• Ebert, E. C. (2009). Infliximab and the TNF-{alpha} system. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G612-G620 [Abstract] [Full Text]  
• Maimon, N., Brunton, J., Chan, A., Marras, T. K (2009). Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. BMJ Case Reports 2009: bcr0920080967-bcr0920080967 [Abstract] [Full Text]  
• Aringer, M, Smolen, J. (2009). TNF inhibition in SLE: where do we stand?. Lupus 18: 5-8  
• Sheen, P., O'Kane, C. M., Chaudhary, K., Tovar, M., Santillan, C., Sosa, J., Caviedes, L., Gilman, R. H., Stamp, G., Friedland, J. S. (2009). High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J 33: 134-141 [Abstract] [Full Text]  
• Ishihara, T., Tanaka, K.-I., Tasaka, Y., Namba, T., Suzuki, J., Ishihara, T., Okamoto, S., Hibi, T., Takenaga, M., Igarashi, R., Sato, K., Mizushima, Y., Mizushima, T. (2009). Therapeutic Effect of Lecithinized Superoxide Dismutase against Colitis. J. Pharmacol. Exp. Ther. 328: 152-164 [Abstract] [Full Text]  
• Salliot, C, Dougados, M, Gossec, L (2009). Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68: 25-32 [Abstract] [Full Text]  
• Sinistro, A., Almerighi, C., Ciaprini, C., Natoli, S., Sussarello, E., Di Fino, S., Calo-Carducci, F., Rocchi, G., Bergamini, A. (2008). Downregulation of CD40 Ligand Response in Monocytes from Sepsis Patients. CVI 15: 1851-1858 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Winfield, R. D., Delano, M. J., Pande, K., Scumpia, P. O., LaFace, D., Moldawer, L. L. (2008). Myeloid-Derived Suppressor Cells in Cancer Cachexia Syndrome: A New Explanation for an Old Problem. JPEN J Parenter Enteral Nutr 32: 651-655 [Abstract] [Full Text]  
• Popov, A., Driesen, J., Abdullah, Z., Wickenhauser, C., Beyer, M., Debey-Pascher, S., Saric, T., Kummer, S., Takikawa, O., Domann, E., Chakraborty, T., Kronke, M., Utermohlen, O., Schultze, J. L. (2008). Infection of Myeloid Dendritic Cells with Listeria monocytogenes Leads to the Suppression of T Cell Function by Multiple Inhibitory Mechanisms. J. Immunol. 181: 4976-4988 [Abstract] [Full Text]  
• Gallegos, A. M., Pamer, E. G., Glickman, M. S. (2008). Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. JEM 205: 2359-2368 [Abstract] [Full Text]  
• Jeong, Y. J., Lee, K. S. (2008). Pulmonary Tuberculosis: Up-to-Date Imaging and Management. Am. J. Roentgenol. 191: 834-844 [Abstract] [Full Text]  
• Carter, J D, Gerard, H C, Hudson, A P (2008). Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis 67: 1181-1183 [Abstract] [Full Text]  
• Samten, B., Townsend, J. C., Sever-Chroneos, Z., Pasquinelli, V., Barnes, P. F., Chroneos, Z. C. (2008). An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell-mediated immune responses to Mycobacterium tuberculosis. J. Leukoc. Biol. 84: 115-123 [Abstract] [Full Text]  
• Leung, C. C., Lam, T. H., Chan, W. M., Yew, W. W., Ho, K. S., Leung, G. M., Law, W. S., Tam, C. M., Chan, C. K., Chang, K. C. (2008). Diabetic Control and Risk of Tuberculosis: A Cohort Study. Am J Epidemiol 167: 1486-1494 [Abstract] [Full Text]  
• Sexton, P., Harrison, A. C. (2008). Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 31: 1322-1333 [Abstract] [Full Text]  
• Welsh, K. J., Abbott, A. N., Hwang, S.-A., Indrigo, J., Armitige, L. Y., Blackburn, M. R., Hunter, R. L., Actor, J. K. (2008). A role for tumour necrosis factor-{alpha}, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response. Microbiology 154: 1813-1824 [Abstract] [Full Text]  
• van Vollenhoven, R. (2008). The Janus of lupus - benefits and risks with B-cell therapy. Lupus 17: 447-449 [Abstract]  
• Burr, M. L., Malaviya, A. P., Gaston, J. H., Carmichael, A. J., Ostor, A. J. K. (2008). Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47: 738-739 [Full Text]  
• Feagan, B. G., Sandborn, W. J., Mittmann, U., Bar-Meir, S., D'Haens, G., Bradette, M., Cohen, A., Dallaire, C., Ponich, T. P., McDonald, J. W. D., Hebuterne, X., Pare, P., Klvana, P., Niv, Y., Ardizzone, S., Alexeeva, O., Rostom, A., Kiudelis, G., Spleiss, J., Gilgen, D., Vandervoort, M. K., Wong, C. J., Zou, G. Y., Donner, A., Rutgeerts, P. (2008). Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease: The EPIC Randomized Controlled Trials. JAMA 299: 1690-1697 [Abstract] [Full Text]  
• Gadkowski, L. B., Stout, J. E. (2008). Cavitary Pulmonary Disease. Clin. Microbiol. Rev. 21: 305-333 [Abstract] [Full Text]  
• Morgan, A.W., Hale, G., Rebello, P.R.U.B., Richards, S.J., Gooi, H.-C., Waldmann, H., Emery, P., Isaacs, J.D. (2008). A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM 101: 299-306 [Abstract] [Full Text]  
• Giansanti, F., Ramazzotti, M., Vannozzi, L., Rapizzi, E., Fiore, T., Iaccheri, B., Degl' Innocenti, D., Moncini, D., Menchini, U. (2008). A Pilot Study on Ocular Safety of Intravitreal Infliximab in a Rabbit Model. IOVS 49: 1151-1156 [Abstract] [Full Text]  
• Chakravarty, S. D., Zhu, G., Tsai, M. C., Mohan, V. P., Marino, S., Kirschner, D. E., Huang, L., Flynn, J., Chan, J. (2008). Tumor Necrosis Factor Blockade in Chronic Murine Tuberculosis Enhances Granulomatous Inflammation and Disorganizes Granulomas in the Lungs. Infect. Immun. 76: 916-926 [Abstract] [Full Text]  
• Newton, S. M., Mackie, S. L., Martineau, A. R., Wilkinson, K. A., Kampmann, B., Fisher, C., Dutta, S., Levin, M., Wilkinson, R. J., Pasvol, G. (2008). Reduction of Chemokine Secretion in Response to Mycobacteria in Infliximab-Treated Patients. CVI 15: 506-512 [Abstract] [Full Text]  
• Tsiodras, S., Samonis, G., Boumpas, D. T., Kontoyiannis, D. P. (2008). Fungal Infections Complicating Tumor Necrosis Factor {alpha} Blockade Therapy. Mayo Clin Proc. 83: 181-194 [Abstract] [Full Text]  
• Dinser, R., Fousse, M., Sester, U., Albrecht, K., Singh, M., Kohler, H., Muller-Ladner, U., Sester, M. (2008). Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-{alpha} blocking drugs using a novel flow-cytometric interferon-{gamma} release assay. Rheumatology (Oxford) 47: 212-218 [Abstract] [Full Text]  
• Takeuchi, T, Tatsuki, Y, Nogami, Y, Ishiguro, N, Tanaka, Y, Yamanaka, H, Kamatani, N, Harigai, M, Ryu, J, Inoue, K, Kondo, H, Inokuma, S, Ochi, T, Koike, T (2008). Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194 [Abstract] [Full Text]  
• Deepe, G. S. Jr., Gibbons, R. S. (2008). TNF-{alpha} Antagonism Generates a Population of Antigen-Specific CD4+CD25+ T Cells That Inhibit Protective Immunity in Murine Histoplasmosis. J. Immunol. 180: 1088-1097 [Abstract] [Full Text]  
• Shibata, H., Yoshioka, Y., Ohkawa, A., Minowa, K., Mukai, Y., Abe, Y., Taniai, M., Nomura, T., Kayamuro, H., Nabeshi, H., Sugita, T., Imai, S., Nagano, K., Yoshikawa, T., Fujita, T., Nakagawa, S., Yamamoto, A., Ohta, T., Hayakawa, T., Mayumi, T., Vandenabeele, P., Aggarwal, B. B., Nakamura, T., Yamagata, Y., Tsunoda, S.-i., Kamada, H., Tsutsumi, Y. (2008). Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-{alpha} Antagonist. J. Biol. Chem. 283: 998-1007 [Abstract] [Full Text]  
• Matulis, G, Juni, P, Villiger, P M, Gadola, S D (2008). Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon {gamma} assay. Ann Rheum Dis 67: 84-90 [Abstract] [Full Text]  
• Sellam, J., Hamdi, H., Roy, C., Baron, G., Lemann, M., Puechal, X., Breban, M., Berenbaum, F., Humbert, M., Weldingh, K., Salmon, D., Ravaud, P., Emilie, D., Mariette, X., for the RATIO (Research Axed on Tolerance of Bioth, (2007). Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66: 1610-1615 [Abstract] [Full Text]  
• Raval, A., Akhavan-Toyserkani, G., Brinker, A., Avigan, M. (2007). Brief Communication: Characteristics of Spontaneous Cases of Tuberculosis Associated with Infliximab. ANN INTERN MED 147: 699-702 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Wong, K. C., Leong, W. M., Law, H. K. W., Ip, K. F., Lam, J. T. H., Yuen, K. Y., Ho, P. L., Tse, W. S., Weng, X. H., Zhang, W. H., Chen, S., Yam, W. C. (2007). Molecular Characterization of Clinical Isolates of Mycobacterium tuberculosis and Their Association with Phenotypic Virulence in Human Macrophages. CVI 14: 1279-1284 [Abstract] [Full Text]  
• Askling, J., Fored, C M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Coster, L., Geborek, P., Jacobsson, L. T, Lindblad, S., Lysholm, J., Rantapaa-Dahlqvist, S., Saxne, T., van Vollenhoven, R. F, Klareskog, L. (2007). Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66: 1339-1344 [Abstract] [Full Text]  
• Doz, E., Rose, S., Nigou, J., Gilleron, M., Puzo, G., Erard, F., Ryffel, B., Quesniaux, V. F. J. (2007). Acylation Determines the Toll-like receptor (TLR)-dependent Positive Versus TLR2-, Mannose Receptor-, and SIGNR1-independent Negative Regulation of Pro-inflammatory Cytokines by Mycobacterial Lipomannan. J. Biol. Chem. 282: 26014-26025 [Abstract] [Full Text]  
• Nugent, K., Diri, E., Tello, W., Ratnoff, W.D. (2007). Letter To the Editor: Infliximab-induced SLE-like syndrome involving the lung and pleura. Lupus 16: 764-766  
• Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., van der Heijde, D., Kishimoto, T. (2007). Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66: 1162-1167 [Abstract] [Full Text]  
• Maimon, N., Brunton, J., Chan, A. K, Marras, T. K (2007). Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 62: 739-740 [Abstract] [Full Text]  
• Lewis, J. D. (2007). Anti-TNF Antibodies for Crohn's Disease -- In Pursuit of the Perfect Clinical Trial. NEJM 357: 296-298 [Full Text]  
• Fremond, C. M., Togbe, D., Doz, E., Rose, S., Vasseur, V., Maillet, I., Jacobs, M., Ryffel, B., Quesniaux, V. F. J. (2007). IL-1 Receptor-Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to Mycobacterium tuberculosis Infection. J. Immunol. 179: 1178-1189 [Abstract] [Full Text]  
• Jacobsen, M., Detjen, A. K., Mueller, H., Gutschmidt, A., Leitner, S., Wahn, U., Magdorf, K., Kaufmann, S. H. E. (2007). Clonal Expansion of CD8+ Effector T Cells in Childhood Tuberculosis. J. Immunol. 179: 1331-1339 [Abstract] [Full Text]  
• Leyten, E. M. S., Arend, S. M., Prins, C., Cobelens, F. G. J., Ottenhoff, T. H. M., van Dissel, J. T. (2007). Discrepancy between Mycobacterium tuberculosis-Specific Gamma Interferon Release Assays Using Short and Prolonged In Vitro Incubation. CVI 14: 880-885 [Abstract] [Full Text]  
• Leung, C. C., Lam, T. H., Chan, W. M., Yew, W. W., Ho, K. S., Leung, G., Law, W. S., Tam, C. M., Chan, C. K., Chang, K. C. (2007). Lower Risk of Tuberculosis in Obesity. Arch Intern Med 167: 1297-1304 [Abstract] [Full Text]  
• Martineau, A. R., Wilkinson, K. A., Newton, S. M., Floto, R. A., Norman, A. W., Skolimowska, K., Davidson, R. N., Sorensen, O. E., Kampmann, B., Griffiths, C. J., Wilkinson, R. J. (2007). IFN-{gamma}- and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of Cathelicidin LL-37. J. Immunol. 178: 7190-7198 [Abstract] [Full Text]  
• Maglione, P. J., Xu, J., Chan, J. (2007). B Cells Moderate Inflammatory Progression and Enhance Bacterial Containment upon Pulmonary Challenge with Mycobacterium tuberculosis. J. Immunol. 178: 7222-7234 [Abstract] [Full Text]  
• Spohn, G., Guler, R., Johansen, P., Keller, I., Jacobs, M., Beck, M., Rohner, F., Bauer, M., Dietmeier, K., Kundig, T. M., Jennings, G. T., Brombacher, F., Bachmann, M. F. (2007). A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-{alpha} Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis. J. Immunol. 178: 7450-7457 [Abstract] [Full Text]  
• Raychaudhuri, S., Shmerling, R., Ermann, J., Helfgott, S. (2007). Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis. Rheumatology (Oxford) 46: 887-888 [Full Text]  
• Wielockx, B., Staelens, J., Puimege, L., Vanlaere, I., Van Roy, M., van Lint, P., Van Roy, F., Libert, C. (2007). Description and Mapping of the Resistance of DBA/2 Mice to TNF-Induced Lethal Shock. J. Immunol. 178: 5069-5075 [Abstract] [Full Text]  
• Leung, C. C., Yew, W. W., Law, W. S., Tam, C. M., Leung, M., Chung, Y. W., Cheung, K. W., Chan, K. W., Fu, F. (2007). Smoking and tuberculosis among silicotic patients. Eur Respir J 29: 745-750 [Abstract] [Full Text]  
• O'Kane, C. M., Boyle, J. J., Horncastle, D. E., Elkington, P. T., Friedland, J. S. (2007). Monocyte-Dependent Fibroblast CXCL8 Secretion Occurs in Tuberculosis and Limits Survival of Mycobacteria within Macrophages. J. Immunol. 178: 3767-3776 [Abstract] [Full Text]  
• Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C. F., Wallace, R. J. Jr., Winthrop, K., on behalf of the ATS Mycobacterial Diseases Subcom, (2007). An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. 175: 367-416 [Full Text]  
• Samuel, L. P., Song, C.-H., Wei, J., Roberts, E. A., Dahl, J. L., Barry, C. E. III, Jo, E.-K., Friedman, R. L. (2007). Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology 153: 529-540 [Abstract] [Full Text]  
• Erin, E. M., Kon, O. M., Barnes, P. J., Hansel, T. T. (2007). . Am. J. Respir. Crit. Care Med. 175: 288a-289 [Full Text]  
• Chakravarty, S. D., Xu, J., Lu, B., Gerard, C., Flynn, J., Chan, J. (2007). The Chemokine Receptor CXCR3 Attenuates the Control of Chronic Mycobacterium tuberculosis Infection in BALB/c Mice. J. Immunol. 178: 1723-1735 [Abstract] [Full Text]  
• Borras-Blasco, J., Nunez-Cornejo, C., Gracia-Perez, A., Rosique-Robles, J D., Castera, M. E., Viosca, E., Abad, F J. (2007). Parapharyngeal Abscess in a Patient Receiving Etanercept. The Annals of Pharmacotherapy 41: 341-344 [Abstract] [Full Text]  
• Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., Dougados, M. (2007). Infections during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46: 327-334 [Abstract] [Full Text]  
• Basu, S., Pathak, S. K., Banerjee, A., Pathak, S., Bhattacharyya, A., Yang, Z., Talarico, S., Kundu, M., Basu, J. (2007). Execution of Macrophage Apoptosis by PE_PGRS33 of Mycobacterium tuberculosis Is Mediated by Toll-like Receptor 2-dependent Release of Tumor Necrosis Factor-{alpha}. J. Biol. Chem. 282: 1039-1050 [Abstract] [Full Text]  
• Fujio, K., Okamoto, A., Araki, Y., Shoda, H., Tahara, H., Tsuno, N. H., Takahashi, K., Kitamura, T., Yamamoto, K. (2006). Gene Therapy of Arthritis with TCR Isolated from the Inflamed Paw. J. Immunol. 177: 8140-8147 [Abstract] [Full Text]  
• Yamada, T, Nakajima, A, Inoue, E, Tanaka, E, Hara, M, Tomatsu, T, Kamatani, N, Yamanaka, H (2006). Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65: 1661-1663 [Abstract] [Full Text]  
• Sester, U., Junker, H., Hodapp, T., Schutz, A., Thiele, B., Meyerhans, A., Kohler, H., Sester, M. (2006). Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 21: 3258-3268 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Baughman, R. P., Drent, M., Kavuru, M., Judson, M. A., Costabel, U., du Bois, R., Albera, C., Brutsche, M., Davis, G., Donohue, J. F., Muller-Quernheim, J., Schlenker-Herceg, R., Flavin, S., Lo, K. H., Oemar, B., Barnathan, E. S., on behalf of the Sarcoidosis Investigators, (2006). Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. Am. J. Respir. Crit. Care Med. 174: 795-802 [Abstract] [Full Text]  
• Huugen, D., Cohen Tervaert, J. W., Heeringa, P. (2006). TNF-{alpha} Bioactivity-Inhibiting Therapy in ANCA-Associated Vasculitis: Clinical and Experimental Considerations. CJASN 1: 1100-1107 [Abstract] [Full Text]  
• Matsumoto, T., Tanaka, T., Kawase, I. (2006). Infliximab for Rheumatoid Arthritis in a Patient with Tuberculosis.. NEJM 355: 740-741 [Full Text]  
• Reinisch, W, Hommes, D W, Van Assche, G, Colombel, J-F, Gendre, J-P, Oldenburg, B, Teml, A, Geboes, K, Ding, H, Zhang, L, Tang, M, Cheng, M, van Deventer, S J H, Rutgeerts, P, Pearce, T (2006). A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon {gamma} antibody, in patients with moderate to severe Crohn's disease. Gut 55: 1138-1144 [Abstract] [Full Text]  
• Iseli, A., Hullstrung, H. D., Rodenhausen, S., Widmer, A. F., Tyndall, A., Hasler, P. (2006). Detection of tuberculosis by extensive screening in a patient with rheumatoid arthritis prior to anti-TNF-{alpha} therapy. Rheumatology (Oxford) 45: 1049-1050 [Full Text]  
• Falconer, H., Mwenda, J.M., Chai, D.C., Wagner, C., Song, X.Y., Mihalyi, A., Simsa, P., Kyama, C., Cornillie, F.J., Bergqvist, A., Fried, G., D'Hooghe, T.M. (2006). Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 21: 1856-1862 [Abstract] [Full Text]  
• Hyrich, K, Symmons, D, Watson, K, Silman, A, BSRBR Control Centre Consortium, , on behalf of the British Society for Rheumatology, (2006). Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 65: 895-898 [Abstract] [Full Text]  
• Lesnik, A., Bolivar, J., Morel, J., Taourel, P. (2006). On the AJR viewbox. Pseudotumoral colonic tuberculosis complicating rheumatoid arthritis treated with a tumor necrosis factor antagonist.. Am. J. Roentgenol. 186: 1799-1800 [Full Text]  
• Schluger, N. W. (2006). Assessing tuberculosis transmission and virulence: the vanishing tuberculin skin test.. Am. J. Respir. Crit. Care Med. 173: 942-943 [Full Text]  
• Feldmann, M., Pusey, C. D. (2006). Is There a Role for TNF-{alpha} in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis? Lessons from Other Chronic Inflammatory Diseases. J. Am. Soc. Nephrol. 17: 1243-1252 [Abstract] [Full Text]  
• Ghosh, S., Chackerian, A. A., Parker, C. M., Ballantyne, C. M., Behar, S. M. (2006). The LFA-1 adhesion molecule is required for protective immunity during pulmonary Mycobacterium tuberculosis infection.. J. Immunol. 176: 4914-4922 [Abstract] [Full Text]  
• Chapgier, A., Wynn, R. F., Jouanguy, E., Filipe-Santos, O., Zhang, S., Feinberg, J., Hawkins, K., Casanova, J.-L., Arkwright, P. D. (2006). Human Complete Stat-1 Deficiency Is Associated with Defective Type I and II IFN Responses In Vitro but Immunity to Some Low Virulence Viruses In Vivo.. J. Immunol. 176: 5078-5083 [Abstract] [Full Text]  
• Goode, S, Tierney, G, Deighton, C (2006). Life threatening intra-abdominal sepsis in patients on anti-TNF-{alpha} therapy. Gut 55: 590-591 [Full Text]  
• Podolsky, D. K., Gonzalez, R. G., Hasserjian, R. P. (2006). Case records of the Massachusetts General Hospital. Case 8-2006. A 71-year-old woman with Crohn's disease and altered mental status.. NEJM 354: 1178-1184 [Full Text]  
• Leyten, E. M. S., Mulder, B., Prins, C., Weldingh, K., Andersen, P., Ottenhoff, T. H. M., van Dissel, J. T., Arend, S. M. (2006). Use of Enzyme-Linked Immunospot Assay with Mycobacterium tuberculosis- Specific Peptides for Diagnosis of Recent Infection with M. tuberculosis after Accidental Laboratory Exposure.. J. Clin. Microbiol. 44: 1197-1201 [Abstract] [Full Text]  
• Chang, J.-S., Huggett, J. F., Dheda, K., Kim, L. U., Zumla, A., Rook, G. A. W. (2006). Myobacterium tuberculosis Induces Selective Up-Regulation of TLRs in the Mononuclear Leukocytes of Patients with Active Pulmonary Tuberculosis.. J. Immunol. 176: 3010-3018 [Abstract] [Full Text]  
• Travis, S P L, Stange, E F, Lemann, M, Oresland, T, Chowers, Y, Forbes, A, D'Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J, for the European Crohn's and Colitis Organisation, (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55: i16-i35 [Abstract] [Full Text]  
• Demissie, A., Leyten, E. M. S., Abebe, M., Wassie, L., Aseffa, A., Abate, G., Fletcher, H., Owiafe, P., Hill, P. C., Brookes, R., Rook, G., Zumla, A., Arend, S. M., Klein, M., Ottenhoff, T. H. M., Andersen, P., Doherty, T. M., the VACSEL Study Group, (2006). Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis. CVI 13: 179-186 [Abstract] [Full Text]  
• Deng, A., Harvey, V., Sina, B., Strobel, D., Badros, A., Junkins-Hopkins, J. M., Samuels, A., Oghilikhan, M., Gaspari, A. (2006). Interstitial Granulomatous Dermatitis Associated With the Use of Tumor Necrosis Factor {alpha} Inhibitors.. Arch Dermatol 142: 198-202 [Abstract] [Full Text]